Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, Kenneth P., Tuveson, David A., Ruhe, Zachary C., Yin, Bob, Willis, Nicholas A., Bronson, Roderick T., Crowley, Denise, Jacks, Tyler·2004·Cell
DOI 10.1016/j.cell.2004.11.004

Cited by (1,000)

Items 601–700 of 1,000

  1. Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis
    Niall M. Corcoran, Michael J. Clarkson, Ryan Stuchbery, Christopher M. Hovens · 2016 · Clinical Cancer Research
  2. p53: Its Mutations and Their Impact on Transcription
    Catherine A. Vaughan, Isabella Pearsall, William Andrew Yeudall, Swati Palit Deb, Sumitra Deb · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
  3. A rare DNA contact mutation in cancer confers p53 gain‐of‐function and tumor cell survival via TNFAIP8 induction
    Jessica Monteith, Hestia S. Mellert, Morgan A. Sammons, Laudita A. Kuswanto, Stephen Matthew Sykes, Lois Resnick‐Silverman, James J. Manfredi, Shelley L. Berger, Steven B. McMahon · 2016 · Molecular Oncology
  4. CHIP promotes autophagy‐mediated degradation of aggregating mutant p53 in hypoxic conditions
    Meenu Maan, Uttam Pati · 2018 · FEBS Journal
  5. Heterozygosity for Hypoxia Inducible Factor 1α Decreases the Incidence of Thymic Lymphomas in a p53 Mutant Mouse Model
    Jessica A. Bertout, Shetal Arvind Patel, Benjamin H. Fryer, Amy C. Durham, Kelly L. Covello, Kenneth P. Olive, Michael H. Goldschmidt, Marie Celeste Simon · 2009 · Cancer Research
  6. Functions of p53 in metabolism and invasion
    Karen H. Vousden · 2009 · Biochemical Society Transactions
  7. Insulin-like growth factor 1 receptor activation promotes mammary gland tumor development by increasing glycolysis and promoting biomass production
    Bas ter Braak, Christine L. E. Siezen, Joo Sang Lee, Pooja Rao, Charlotte Voorhoeve, Eytan Ruppin, Jan Willem van der Laan, Bob van de Water · 2017 · Breast Cancer Research
  8. The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants.
    Madison Miller, Nitin H. Shirole, Ruxiao Tian, Debjani Pal, Raffaella Sordella · 2016 · PubMed
  9. Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma
    Michael Olvedy, Julie C. Tisserand, Flavie Luciani, Bram Boeckx, Jasper Wouters, Sophie Lopez, Florian Rambow, Sara Aibar, Bernard Thienpont, Jasmine Barra et al. · 2017 · Journal of Clinical Investigation
  10. Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73
    Avinashnarayan Venkatanarayan, Payal Raulji, William Norton, Elsa Renee Flores · 2015 · Cell Cycle
  11. Progression from cirrhosis to cancer is associated with early ubiquitin post‐translational modifications: identification of new biomarkers of cirrhosis at risk of malignancy
    Samira Laouirem, Julie Le Faouder, Theodore Alexandrov, Denis Mestivier, Thibaut Léger, Xavier Baudin, Mouniya Mebarki, Valérie Paradis, Jean‐Michel Camadro, Pierre Bédossa · 2014 · The Journal of Pathology
  12. Mutant p53 Protects Cells from 12- O -Tetradecanoylphorbol-13-Acetate–Induced Death by Attenuating Activating Transcription Factor 3 Induction
    Yosef Buganim, Eyal Kalo, Ran Brosh, Hila Besserglick, Ido Nachmany, Yoach Rais, Perry Stambolsky, Xiaohu Tang, Michael Milyavsky, Igor Shats et al. · 2006 · Cancer Research
  13. Human Umbilical Cord Matrix Stem Cells Maintain Multilineage Differentiation Abilities and Do Not Transform during Long-Term Culture
    Isabelle Scheers, Catherine Anne Lombard, Massimiliano Paganelli, David Campard, Mustapha Najimi, Jean‐Luc Gala, Anabelle Decottignies, Etienne Marc Sokal · 2013 · PLoS ONE
  14. Mutant p53 gain of function: The NF-Y connection
    Melissa J. Peart, Carol L. Prives · 2006 · Cancer Cell
  15. Acetylation of the Cell-Fate Factor Dachshund Determines p53 Binding and Signaling Modules in Breast Cancer
    Ke Chen, Kongming Wu, Michael Gormley, Adam Ertel, Jing Wang, Wei Zhang, Jie Zhou, Gabriele DiSante, Zhiping Li, Hallgeir Rui et al. · 2013 · Oncotarget
  16. Lung-Enriched Mutations in the p53 Tumor Suppressor: A Paradigm for Tissue-Specific Gain of Oncogenic Function
    Julie A. Barta, Steven B. McMahon · 2018 · Molecular Cancer Research
  17. Ceramide–Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations
    Sachin Khiste, Zhijun Liu, Kartik R. Roy, Mohammad B. Uddin, Salman B. Hosain, Xin Gu, Sami Nazzal, Ronald A. Hill, Yu Liu · 2019 · Molecular Cancer Therapeutics
  18. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
    Eva Crespo-Rodriguez, Katharina F. Bergerhoff, Galabina Bozhanova, Shane Foo, Emmanuel Christian Patin, Harriet Whittock, Richard Buus, Syed Aleem Haider, Gareth Muirhead, Khin Thway et al. · 2020 · Journal for ImmunoTherapy of Cancer
  19. Identification of a Novel Germ Line Variant Hotspot Mutant p53-R175L in Pediatric Adrenal Cortical Carcinoma
    Alina Nico West, Raul Correa Ribeiro, Jesse Jenkins, Carlos Rodriguez Galindo, Bonald Cavalcante de Figueiredo, Richard W. Kriwacki, Gerard P. Zambetti · 2006 · Cancer Research
  20. The African-specific S47 polymorphism of p53 alters chemosensitivity
    Subhasree Basu, Thibaut Barnoud, Che-Pei Kung, Matthew Reiss, Maureen E. Murphy · 2016 · Cell Cycle
  21. BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation
    Reischmann, Nadine, Andrieux, Geoffroy, Griffin, Ricarda, Reinheckel, Thomas, Boerries, Melanie, Brummer, Tilman · 2020 · Oncogene
  22. Deciphering the significance of p53 mutant proteins
    Alessio Butera, Ivano Amelio · 2024 · Trends in Cell Biology
  23. Crosstalk among p53 family members in cutaneous carcinoma
    Caterina Missero, Dario Antonini · 2014 · Experimental Dermatology
  24. p53-R273H upregulates neuropilin-2 to promote cell mobility and tumor metastasis
    Tao� Lv, Xianqiang Wu, Lijuan Sun, Qingyong Hu, Yang Wan, Liang Wang, Zhiqiang Zhao, Xiao Tu, Zhi‐Xiong Jim Xiao · 2017 · Cell Death and Disease
  25. Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma
    Nilay S. Sethi, Osamu Kikuchi, James M. McFarland, Yanxi Zhang, Max Chung, Nicholas Kafker, Mirazul Islam, Benjamin L. Lampson, Abhishek A. Chakraborty, William G. Kaelin et al. · 2019 · JCI Insight
  26. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice
    Olga Kim, Eun Young Park, David L. Klinkebiel, Svetlana Pack, Yong-Hyun Shin, Zied Abdullaev, Robert E. Emerson, Donna M. Coffey, Sun Young Kwon, Chad J. Creighton et al. · 2020 · PLoS Genetics
  27. Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe
    Elmira Roshani Asl, Davoud Rostamzadeh, Pascal H. G. Duijf, Sahar Mafi, Behnaz Mansoori, Shirin Barati, William Chi Shing Cho, Behzad Mansoori · 2023 · Life Sciences
  28. Long Non-Coding RNAs Embedded in the Rb and p53 Pathways
    Murugan Subramanian, Matthew F. Jones, Ashish Lal · 2013 · Cancers
  29. p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells
    Shui Ping Tu, Alfred L. Chi, Walden Ai, Shigeo Takaishi, Zinaida A. Dubeykovskaya, Michael Quante, James G. Fox, Timothy Cragin Wang · 2009 · American Journal of Physiology-Gastrointestinal and Liver Physiology
  30. FGFR inhibition augments anti–PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression
    Atsushi Okato, Takanobu Utsumi, Michela Ranieri, Xingnan Zheng, Mi Zhou, Luiza Doro Pereira, Ting Chen, Yuki Kita, Di Wu, Hyesun Hyun et al. · 2024 · Journal of Clinical Investigation
  31. AKT regulates NPM dependent ARF localization and p53mut stability in tumors
    Garth Hamilton, Aswin Abraham, Jennifer P. Morton, Oliver L. Sampson, Dafni‐Eleftheria Pefani, Svetlana V. Khoronenkova, Anna M. Grawenda, Angelos Papaspyropoulos, Nigel Balfour Jamieson, Colin J. McKay et al. · 2014 · Oncotarget
  32. Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis
    Yoshihiro Nishikawa, Yuzo Kodama, Masahiro Shiokawa, Tomoaki Matsumori, Saiko Marui, Katsutoshi Kuriyama, Takeshi Kuwada, Yuko Sogabe, Nobuyuki Kakiuchi, Teruko Tomono et al. · 2019 · Oncogene
  33. p53 balances between tissue hierarchy and anarchy
    Gabriela Koifman, Ronit Aloni-Grinstein, Varda Rotter · 2019 · Journal of Molecular Cell Biology
  34. Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy
    Aya Saleh, Ruth Perets · 2021 · Cancers
  35. MicroRNAs in Cancer Translational Research
    William Chi Shing Cho · 2011 · Springer eBooks
  36. Prospects for p53-based cancer therapy.
    Tomasz Stokłosa, Jakub Gołąb · 2005 · Acta Biochimica Polonica
  37. Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks
    Xiao Ling Li, Matthew F. Jones, Murugan Subramanian, Ashish Lal · 2014 · FEBS Letters
  38. Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53
    Shaoxiong Chen, Rui Gao, C Yao, Michihiro Kobayashi, Stephen Z. Liu, Mervin C. Yöder, Hal E. Broxmeyer, Reuben Kapur, H. Scott Boswell, Lindsey D. Mayo et al. · 2017 · Leukemia
  39. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma
    Alexander Jethwa, Mikolaj Michal Slabicki, Jennifer Hüllein, Marius Jentzsch, Vineet Dalal, Sophie Rabe, Lena Wagner, Tatjana Walther, Wolfram Klapper, MMML Network Project et al. · 2018 · Blood
  40. RNA sequencing of Sleeping Beauty transposon-induced tumors detects transposon-RNA fusions in forward genetic cancer screens
    N. Temiz, B. Moriarity, Natalie K. Wolf, Jesse D. Riordan, A. Dupuy, D. Largaespada, A. Sarver · 2016 · Genome Research
  41. Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation
    Juan Liu, Yiyun Shen, Jie Liu, Dandan Xu, Chun‐Yuan Chang, Jianming Wang, Jason Zhou, Bruce George Haffty, Lanjing Zhang, Jill Bargonetti et al. · 2025 · Nature Communications
  42. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
    Swathi V. Iyer, Alejandro Parrales, Priya Begani, Akshay Narkar, Amit S. Adhikari, Luis A. Martinez, Tomoo Iwakuma · 2015 · Oncotarget
  43. cFOS-SOX9 Axis Reprograms Bone Marrow-Derived Mesenchymal Stem Cells into Chondroblastic Osteosarcoma
    Yunlong He, Wentao Zhu, Min Hwa Shin, Joy M. Gary, Chengyu Liu, Wendy Dubois, Shelley B. Hoover, Shunlin Jiang, Eryney Marrogi, Beverly A. Mock et al. · 2017 · Stem Cell Reports
  44. Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant p53 by Downregulating PTEN
    Jin Zhang, Enshun Xu, Cong Ren, Hee Jung Yang, Yanhong Zhang, Wenqiang Sun, Xiangmudong Kong, Weici Zhang, Mingyi Chen, Eric C. Huang et al. · 2018 · Cancer Research
  45. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
    Li Ren Kong, Richard Ong, Tuan Zea Tan, Nur Afiqah Binte Mohamed Salleh, Matan Thangavelu Thangavelu, Jane Vin Chan, Lie Yong Judice Koh, Giridharan Periyasamy, Jieying Amelia Lau, Thi Bich Uyen Le et al. · 2020 · Nature Communications
  46. Identification of a druggable protein–protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1
    Xin Tong, Dandan Xu, Rama K. Mishra, Ryan Jones, Leyu Sun, Gary E. Schiltz, Jie Liao, Guang‐Yu Yang · 2020 · Journal of Biological Chemistry
  47. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity
    Tamara Isermann, Özge Cicek Sener, Adrian Stender, Luisa Klemke, Nadine Winkler, Albrecht Neeße, Jinyu Li, Florian Wegwitz, Ute Martha Moll, Ramona Schulz‐Heddergott · 2021 · Nature Communications
  48. Polyoma Virus-Induced Osteosarcomas in Inbred Strains of Mice: Host Determinants of Metastasis
    Palanivel Velupillai, Chang Kyoo Sung, Yu Tian, Jean Dahl, John Carroll, Roderick Terry Bronson, Thomas L. Benjamin · 2010 · PLoS Pathogens
  49. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner
    Sue Haupt, Catherine Mitchell, Vincent Corneille, Jake Shortt, Stephen B. Fox, Pier Paolo Pandolfi, Mireia Castillo-Martín, Dennis M. Bonal, Carlos Cordon-Carlo, Guillermina Lozano et al. · 2013 · Cell Cycle
  50. The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo
    Ming Kei Lee, Kanaga Sabapathy · 2008 · Journal of Cell Science
  51. Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes
    V. Haley, David Barnes, Ionel Sandovici, Miguel Constância, Christopher F. Graham, Francesco Pezzella, Claudia Bühnemann, Emma J. Carter, Andrew Bassim Hassan · 2012 · EMBO Molecular Medicine
  52. Dihydrosanguinarine suppresses pancreatic cancer cells via regulation of mut-p53/WT-p53 and the Ras/Raf/Mek/Erk pathway
    Sizhi Wu, Huachong Xu, Xianlin Wu, Pei Liu, Yucong Shi, Peng Pang, Li Deng, Guang‐Xiong Zhou, Xiaoyin Chen · 2019 · Phytomedicine
  53. Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses
    Oleg N. Timofeev, Boris Klimovich, Jean Schneikert, Michael Wanzel, Evangelos Pavlakis, Julia Noll, Samet Mutlu, Sabrina Elmshäuser, Andrea Nist, Marco Mernberger et al. · 2019 · The EMBO Journal
  54. Mtbp haploinsufficiency in mice increases tumor metastasis
    Tomoo Iwakuma, Y Tochigi, Carolyn S. Van Pelt, Lisa C. Caldwell, Tamara Terzian, John M. Parant, Gilda P. Chau, Joanna Gail Koch, Christine M. Eischen, Guillermina Lozano · 2007 · Oncogene
  55. p53 in colorectal cancer: from a master player to a privileged therapy target
    Sicheng Yan, Fuyuan Zhan, Yuxuan He, Yuehong Zhu, Zhihong Ma · 2025 · Journal of Translational Medicine
  56. Tracing the origins of metastasis
    Don X. Nguyen · 2010 · The Journal of Pathology
  57. Inactivation ofBrca2cooperates withTrp53R172Hto induce invasive pancreatic ductal adenocarcinomas in mice
    Georg Feldmann, Collins A. Karikari, Marco Dal Molin, Stephanie Duringer, Petra Volkmann, Detlef Klaus Bartsch, Savita Bisht, Jan-Bart M. Koorstra, Peter Brossart, Anirban Maitra et al. · 2011 · Cancer Biology & Therapy
  58. Overexpression of p53 protein in human tumors
    Keiji Inoue, Atsushi Kurabayashi, Taro Shuin, Yuji Ohtsuki, Mutsuo Furihata · 2012 · Medical Molecular Morphology
  59. Trp53 Haploinsufficiency Modifies EGFR-Driven Peripheral Nerve Sheath Tumorigenesis
    Eric P. Rahrmann, Branden S. Moriarity, George Maxwell Otto, Adrienne L. Watson, Kwangmin Choi, Margaret H. Collins, Margaret R. Wallace, Beau R. Webber, Colleen L. Forster, Anthony E. Rizzardi et al. · 2014 · American Journal Of Pathology
  60. A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis
    Xuetian Yue, Yuhan Zhao, Grace C. Huang, Jun Li, Junlan Zhu, Zhaohui Feng, Wenwei Hu · 2016 · Cell Discovery
  61. Mutant p53 antagonizes p63/p73-mediated tumor suppression via Notch1
    Jin Zhang, Wenqiang Sun, Xiangmudong Kong, Yanhong Zhang, Hee Jung Yang, Cong Ren, Yuqian Jiang, Mingyi Chen, Xinbin Chen · 2019 · Proceedings of the National Academy of Sciences
  62. BRCA1/P53: Two strengths in cancer chemoprevention
    Liliana Raimundo, Helena Ramos, Joana B. Loureiro, Juliana Calheiros, Lucı́lia Saraiva · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  63. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8
    Yunjiao Zhang, Xiaowan Huang, Liansheng Wang, Cong Cao, Hao Zhang, Pengfei Wei, He Ding, Yang Song, Ziying Chen, Jieying Qian et al. · 2021 · Biomaterials
  64. Dissecting the p53-Mdm2 feedback loop in vivo : uncoupling the role in p53 stability and activity
    Vinod Pant, Guillermina Lozano · 2014 · Oncotarget
  65. p53: a molecular marker for the detection of cancer
    Mark T. Boyd, Nikolina Vlatković · 2008 · Expert Opinion on Medical Diagnostics
  66. Increased p53 transcription prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter
    Kristy Boggs, David Reisman · 2005 · Oncogene
  67. p53 and its mutants on the slippery road from stemness to carcinogenesis
    Alina Molchadsky, Varda Rotter · 2017 · Carcinogenesis
  68. Does control of mutant p53 by Mdm2 complicate cancer therapy?: Figure 1.
    Carol L. Prives, Eileen White · 2008 · Genes & Development
  69. Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein�18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells
    Sangyan Chen, Yan Zhao, Fang Shen, Dan Long, Ting Yu, Xuechi Lin · 2019 · Oncology Reports
  70. Targeted Apc;Twist Double-Mutant Mice: A New Model of Spontaneous Osteosarcoma That Mimics the Human Disease
    Natacha Entz‐Werlé, Philippe Choquet, Agnès Neuville, Sabine Kuchler‐Bopp, François Clauss, Jean-Marc Danse, Pauline Simo‐Noumbissie, Éric Guérin, Marie‐Pierre Gaub, Jean‐Noël Freund et al. · 2010 · Translational Oncology
  71. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer
    Sharon Wang, Jeff C. Liu, Danbi Kim, Alessandro Datti, Eldad Zacksenhaus · 2016 · Breast Cancer Research
  72. In Vivo Imaging in Pharmaceutical Development and Its Impact on the 3Rs
    Barry R. Campbell, D. E. González Trotter, Catherine D. G. Hines, Wenping Li, Manishkumar R. Patel, Weisheng Zhang, Jeffrey L. Evelhoch · 2016 · ILAR Journal
  73. Enhancing Chemotherapy of p53‐Mutated Cancer through Ubiquitination‐Dependent Proteasomal Degradation of Mutant p53 Proteins by Engineered ZnFe‐4 Nanoparticles
    Jieying Qian, Wenbin Zhang, Pengfei Wei, Guangyu Yao, Tianxiang Yi, Hao Zhang, He Ding, Xiaowan Huang, Meimei Wang, Yang Song et al. · 2020 · Advanced Functional Materials
  74. CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
    Ashwini Makhale, Devathri M. Nanayakkara, Prahlad V. Raninga, Kum Kum Khanna, Murugan Kalimutho · 2021 · International Journal of Molecular Sciences
  75. Acquired αSMA Expression in Pericytes Coincides with Aberrant Vascular Structure and Function in Pancreatic Ductal Adenocarcinoma
    Vikneshwari Natarajan, Sangdeuk Ha, Alexander Delgado, Reed I. Jacobson, Lina Alhalhooly, Yongki Choi, Jiha Kim · 2022 · Cancers
  76. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma
    Vladimir V. Ternovoi, David T. Curiel, Bruce Frederic Smith, Gene P. Siegal · 2006 · Laboratory Investigation
  77. Insights into Wild-Type and Mutant p53 Functions Provided by Genetically Engineered Mice
    Lawrence A. Donehower · 2014 · Human Mutation
  78. Myc, Aurora Kinase A, and mutant p53R172H co-operate in a mouse model of metastatic skin carcinoma
    Enrique C. Torchia, Carlos Caulı́n, Sergio Acı́n, Tamara Terzian, Bradley J. Kubick, Neil F. Box, Dennis R. Roop · 2011 · Oncogene
  79. Genetically modified mouse models of cancer invasion and metastasis
    Paulina Rampetsreiter, Emilio Casanova, Robert Eferl · 2011 · Drug Discovery Today Disease Models
  80. p53 and chemosensitivity in bladder cancer
    Hiroyuki Nishiyama, Jun Watanabe, Osamu Ogawa · 2008 · International Journal of Clinical Oncology
  81. Measurement of tumor-associated mutations in the nasal mucosa of rats exposed to varying doses of formaldehyde
    Fanxue Meng, Edilberto Bermudez, Page B. McKinzie, Melvin E. Andersen, Harvey J. Clewell III M.A., Barbara L. Parsons · 2010 · Regulatory Toxicology and Pharmacology
  82. p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo
    Jesús Pérez‐Losada, Di Wu, Reyno Delrosario, Allan Balmain, Jian‐Hua Mao · 2005 · Oncogene
  83. Mouse models in colon cancer, inferences, and implications
    Melanie H. Kucherlapati · 2023 · iScience
  84. Weighted gene coexpression network analysis and machine learning reveal oncogenome associated microbiome plays an important role in tumor immunity and prognosis in pan-cancer
    Shi-Wei Guan, Quan Lin, Xidong Wu, Haibo Yu · 2023 · Journal of Translational Medicine
  85. Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma
    Guilhem Bousquet, Morad El Bouchtaoui, Christophe Lebœuf, Maxime Battistella, Mariana Varna, Irmine Ferreira, Louis‐François Plassa, Diaddin Hamdan, Philippe Bertheau, Jean‐Paul Feugeas et al. · 2015 · Oncotarget
  86. A novel TP53 variant (rs78378222 A > C) in the polyadenylation signal is associated with increased cancer susceptibility: evidence from a meta-analysis
    Ying Wang, Xuesong Wu, Jing He, Tianjiao Ma, Wei Lei, Zhenya Shen · 2016 · Oncotarget
  87. p53 in the game of transposons
    Annika Wylie, Amanda E. Jones, John Abrams · 2016 · BioEssays
  88. Complexes formed by mutant p53 and their roles in breast cancer
    Arianna Bellazzo, Daria Sicari, Elena Valentino, Giannino Del Sal, Licio Collavin · 2018 · Breast Cancer Targets and Therapy
  89. Mutant p53 amplifies a dynamin-1/APPL1 endosome feedback loop that regulates recycling and migration
    Ashley M. Lakoduk, Philippe Roudot, Marcel Mettlen, Heather M. Grossman Verner, Sandra L. Schmid, Ping‐Hung Chen · 2019 · The Journal of Cell Biology
  90. Murine models of clonal haematopoiesis to assess mechanisms of cardiovascular disease
    Ying Wang, Soichi Sano, Hayato Ogawa, Keita Horitani, Megan A. Evans, Yoshimitsu Yura, Emiri Miura‐Yura, Heather Doviak, Kenneth Walsh · 2021 · Cardiovascular Research
  91. ATG7 is a haploinsufficient repressor of tumor progression and promoter of metastasis
    Jaclyn S. Long, Elżbieta Kania, David G. McEwan, Valentin J.A. Barthet, Martina Brucoli, Marcus J.G.W. Ladds, Christoph Nössing, Kevin M. Ryan · 2022 · Proceedings of the National Academy of Sciences
  92. Non-canonical functions of SNAIL drive context-specific cancer progression
    M. Paul, C. Schneeweis, C. Falcomatà, Chuan Shan, Daniel Rossmeisl, Stella Koutsouli, Christine Klement, M. Żukowska, Sebastian A. Widholz, M. Jesinghaus et al. · 2023 · Nature Communications
  93. Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types
    Keiju Sasaki, Shinʼ ichi Takahashi, Kota Ouchi, Yasufumi Otsuki, Shonosuke Wakayama, Chikashi Ishioka · 2023 · Scientific Reports
  94. Zn(II)-curc targets p53 in thyroid cancer cells
    Alessia Garufi, Valerio D’Orazi, Alessandra Crispini, Gabriella D’Orazi · 2015 · International Journal of Oncology
  95. Modulating the p53 pathway
    Anwesha Dey, David Philip Lane, Chandra Shekhar Verma · 2010 · Seminars in Cancer Biology
  96. The utility of transposon mutagenesis for cancer studies in the era of genome editing
    Gina M. DeNicola, Florian A. Karreth, David J. Adams, Chi C. Wong · 2015 · Genome biology
  97. PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity
    Sarah Croessmann, Hong Yuen Wong, Daniel J. Zabransky, David T. W. Chu, D. Marc Rosen, Justin R. Cidado, Rory L. Cochran, William Brian Dalton, Bracha Erlanger Avigdor, Karen Cravero et al. · 2017 · Breast Cancer Research and Treatment
  98. Dichotomies in cancer research: some suggestions for a new synthesis
    Michael B. Sporn · 2006 · Nature Clinical Practice Oncology
  99. The Untapped Potential of Genetically Engineered Mouse Models in Chemoprevention Research: Opportunities and Challenges
    Cory T. Abate-Shen, Powel H. Brown, Nancy H. Colburn, Eugene W. Gerner, Jeffery E. Green, Martin Lipkin, William G. Nelson, David W. Threadgill · 2008 · Cancer Prevention Research
  100. Discussion of some ‘knowns’ and some ‘unknowns’ about the tumour suppressor p53
    Elizabeth Lieschke, Zilu Wang, Gemma L. Kelly, Andreas Strasser · 2018 · Journal of Molecular Cell Biology